Ross Moat - Sep 4, 2025 Form 4 Insider Report for Kiniksa Pharmaceuticals International, plc (KNSA)

Signature
/s/ Aaron Young, Attorney-in-Fact
Stock symbol
KNSA
Transactions as of
Sep 4, 2025
Transactions value $
-$124,397
Form type
4
Date filed
9/8/2025, 04:37 PM
Previous filing
Sep 3, 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Moat Ross CHIEF CORP. & COMM. OFFICER 23 OLD BOND STREET, THIRD FLOOR, LONDON, UNITED KINGDOM /s/ Aaron Young, Attorney-in-Fact 2025-09-08 0001857177

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Ordinary Share Sale -$124K -3.52K -27.23% $35.31 9.42K Sep 4, 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on November 13, 2024.